🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Turkey / NCT07513363
Starting soon Not applicable

The Role of Urinary RhoA, NGF, and BDNF Levels in Overactive Bladder and Vitamin D Deficiency

NCT07513363 · tracked via the Priya Life Science Turkey tracker
Sponsor
Tarik Emre Sener
Phase
Not applicable
Started
2026-05-01
Last updated
2026-04-07

Condition(s) studied

Overactive BladderVitamin D Deficiency

Investigational drug(s) / intervention(s)

Urotherapy

Urotherapy: Diagnosis and first-line treatment (urotherapy) will be conducted per European Association of Urology (EAU) guidelines.

Study summary

The primary aim of this study is to evaluate the role of three specific urinary proteins-RhoA, Nerve Growth Factor (NGF), and Brain-Derived Neurotrophic Factor (BDNF)-as potential biomarkers for the diagnosis and follow-up of children aged 4-18 diagnosed with Overactive Bladder (OAB) and Vitamin D deficiency.

Eligibility

Sex
ALL
Min age
—
Max age
18 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Children aged 4-18 years presenting with active OAB symptoms (frequency, urgency) Exclusion Criteria: * Neurological diseases * Malignancy * Active urinary tract infections * Anatomical bladder anomalies * History of prior OAB treatment/urological surgery.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Marmara University School of Medicine Urology Department Pendik Istanbul

More Tarik Emre Sener trials in Turkey

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07513363 on ClinicalTrials.gov ↗ ← All trials in Turkey